Description

Semaglutide injection 2 mg/3 mL (0.68 mg/mL) pre-filled pen is a prescription GLP-1 receptor agonist injection used primarily to help improve blood sugar control in adults with type 2 diabetes when prescribed as part of an appropriate treatment plan. The 2 mg/3 mL pen contains semaglutide at a concentration of 0.68 mg/mL and is designed to deliver 0.25 mg or 0.5 mg doses, depending on the prescribed regimen. Current U.S. labeling confirms that this particular pen is not the 2 mg-per-injection pen; the 2 mg dose is supplied in a different 8 mg/3 mL (2.68 mg/mL) pen. What Is Semaglutide Injection 2 mg/3 mL (0.68 mg/mL)? Semaglutide is a GLP-1 receptor agonist that works on pathways involved in blood-glucose regulation and appetite. The medicine is administered subcutaneously, meaning it is injected under the skin. The semaglutide 2 mg/3 mL (0.68 mg/mL) pre-filled pen is a multi-dose, single-patient-use pen. Depending on the pen configuration, it can provide four 0.25 mg doses and two 0.5 mg doses, or four 0.5 mg doses . For buyers comparing products online, checking the total strength, concentration, dose delivered per injection, manufacturer, prescription status, and packaging is important. A product described as “2 mg/3 mL” should not automatically be interpreted as a 2 mg weekly injection. What Is Semaglutide Injection Used For? The current FDA labeling for Ozempic states that semaglutide injection is indicated, alongside diet and exercise, to improve glycemic control in adults with type 2 diabetes. It is also indicated in specified adults with type 2 diabetes and established cardiovascular disease to reduce the risk of major cardiovascular events, and in specified adults with type 2 diabetes and chronic kidney disease to reduce certain kidney and cardiovascular risks. Semaglutide products can have different approved indications, strengths and dosing schedules. Therefore, consumers should not assume that every semaglutide injection is interchangeable with every other semaglutide product. Key Benefits of Semaglutide When prescribed appropriately, potential benefits may include: Improved blood-glucose control: Semaglutide can help adults with type 2 diabetes achieve better glycemic control when combined with diet and exercise. Once-weekly administration: The labeled injection schedule is once weekly, which can be convenient compared with medicines requiring more frequent administration. Cardiovascular risk reduction for certain patients: Current labeling includes reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Kidney-related benefits for certain patients: The current label includes reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in specified adults with type 2 diabetes and chronic kidney disease. Appetite and weight effects: Semaglutide can affect appetite and food intake. However, the appropriate semaglutide product and indication for chronic weight management should be determined by a healthcare professional rather than inferred from the concentration printed on a pen. How Is the Pre-Filled Pen Used? Semaglutide injection is administered subcutaneously in areas such as the abdomen, thigh or upper arm. The prescribed dose should be followed exactly; patients should not change the dose based on the concentration or pen size alone. For the 2 mg/3 mL (0.68 mg/mL) pen, the device is designed for 0.25 mg or 0.5 mg dose delivery rather than a 2 mg injection. Patients should receive appropriate instruction from their healthcare provider before using the pen. A new needle should be used for each injection, and the pen must not be shared with another person, even if the needle is replaced. If a dose is missed, current U.S. labeling instructs patients to administer it within 5 days; if more than 5 days have passed, the missed dose should be skipped and the regular weekly schedule resumed. Semaglutide Side Effects The most common side effects are gastrointestinal. Depending on the patient and dose, these can include: Nausea Vomiting Diarrhea Abdominal pain Constipation Reduced appetite More serious risks are also described in the prescribing information. These include acute pancreatitis, diabetic retinopathy complications, gallbladder-related problems, kidney injury associated with dehydration, and serious gastrointestinal adverse reactions. Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2), as well as in those with a serious hypersensitivity reaction to semaglutide or its ingredients.